Publications

Preclinical
Festival of Biologics
March 5, 2026
ZW1528: A Dual-Targeting Bispecific Antibody to Broadly Suppress Airway Inflammation by Inhibiting IL-4Ra and IL-33 Pathways
Robert Nechanitzky
Preclinical
Festival of Biologics
March 4, 2026
Engineering Next-Generation T Cell Engagers: A Trispecific Platform for Cancer Immunotherapy
Anna von Rossum, Ph.D.
Preclinical, ZW191
World ADC London
February 25, 2026
Design of ZW191: Preclinical Insights and Clinical Potential
Stuart Barnscher
Preclinical
Tumor Models Summit
January 29, 2026
Design of a Next Generation Tumor Targeted Masked IL-12Fc for Enhanced Tolerability and Localized Anti-Tumor Activity
Escalante et al.
Preclinical
Tumor Models Summit
January 29, 2026
Advancing ZW209 Trispecific Design with In Vitro & In Vivo Models to Improve DLL3-Directed Responses
Hernaez et al.
Preclinical
PepTalk
January 22, 2026
Engineering Next-Generation T Cell Engagers: A Trispecific Platform for Cancer Immunotherapy
Clinical
ASCO GI
January 9, 2026
A Phase 1, First-in-Human, Multicenter Study of ZW251, a Novel Glypican-3 (GPC3)-Targeted Antibody-Drug Conjugate (ADC), in Participants With Hepatocellular Carcinoma (HCC)
Chandana et al.
Clinical
ASCO GI
January 8, 2026
Zanidatamab + chemotherapy ± tislelizumab for first-line HER2-positive locally advanced, unresectable, or metastatic gastroesophageal adenocarcinoma: Primary analysis from HERIZON-GEA-01
Elimova et al.
Preclinical
World ADC San Diego
November 5, 2025
ZW327 – A Topoisomerase-1 inhibitor ADC Designed to Target Ly6E-Expressing Tumors
Stuart Barnscher
Preclinical
SITC
November 8, 2025
TriTCE Co-stim: A differentiated T cell engager platform with conditional cis CD28 co-stimulation and transferability to diverse targeting strategies
Verstraete et al.
Preclinical
November 7, 2025
Design of a Next Generation Tumor Targeted Masked IL-12Fc for Enhanced Tolerability and Localized Anti-Tumor Activity
Escalante et al.
Preclinical
SITC
November 7, 2025
High-throughput quantitative characterization of cytotoxic antibody-drug conjugates using spheroid models reveals important considerations in potential molecular mechanisms of ADC resistance
Church et al.